Clinical Trials
1,605 trialsA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
MK-3475-G21
Merck Sharp & Dohme LLC
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
DUET-MEL
Beijing Biotech
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
Actelion
RELATIVITY-127
Bristol-Myers Squibb
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
Bristol-Myers Squibb
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Philogen S.p.A.
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
PHOENIX-ECP
Therakos LLC
MK-3475-051
Merck Sharp & Dohme LLC
DP-04
AstraZeneca
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
Lumos Pharma
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
A Study of ASP1012 in Adults With Solid Tumors
Astellas Pharma Inc
SUPRAME
Immatics US, Inc.
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
KEYMAKER-U02
Merck Sharp & Dohme LLC
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Amgen
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
Sandoz
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
STARTRK-2
Hoffmann-La Roche
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Aura Biosciences
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Kupando GmbH
Resimmune®
Virogen Biotechnology Inc.
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
A Study of BI 3810944 in Patients With Advanced Cancer
Boehringer Ingelheim
OP-NEU-101
Onchilles Pharma Inc
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Biocon Limited
ACTengine
Immatics US, Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.